The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Allied Market Research published a report, titled, "Cytogenetics Market by Product (Consumable, Instrument, Software and Service), by Technique (Comparative Genome Hybridization, Fluorescence in Situ ...

This study provides a valuable new resource to investigate the molecular basis of the particular features characterizing the pipefish embryo. The authors found both unique and shared gene expression ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Molecular Instruments® (MI), founded by the inventor of the HCR™ technology, today announces the launch of the HCR™ Gold and ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to NeoGenomics (NEO – Research Report). The company’s shares ...

Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

The Market research collection of Report Ocean has recently included the “Saudi Arabia Tissue Diagnostic Market” Size, Scope, and Forecast 2024-2032 report. This report, prepared by industry experts ...

The researchers also noted that patients with IHC 2+ and in situ hybridization-amplified disease derived less benefit from T-DM1 compared to the IHC 3+ population, suggesting a need for more ...